Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

PURPOSE: Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this study was to assess the activity of avelumab, a PD-L1 inhibitor, in patients with MBC. METHODS: In a phase 1 trial (JAV...

Descripción completa

Detalles Bibliográficos
Autores principales: Dirix, Luc Y., Takacs, Istvan, Jerusalem, Guy, Nikolinakos, Petros, Arkenau, Hendrik-Tobias, Forero-Torres, Andres, Boccia, Ralph, Lippman, Marc E., Somer, Robert, Smakal, Martin, Emens, Leisha A., Hrinczenko, Borys, Edenfield, William, Gurtler, Jayne, von Heydebreck, Anja, Grote, Hans Juergen, Chin, Kevin, Hamilton, Erika P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807460/
https://www.ncbi.nlm.nih.gov/pubmed/29063313
http://dx.doi.org/10.1007/s10549-017-4537-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807460/
https://www.ncbi.nlm.nih.gov/pubmed/29063313
http://dx.doi.org/10.1007/s10549-017-4537-5

Ejemplares similares